Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vicarious Surgical Inc. (RBOT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public surgical robotics and medical device developer. These filings offer detailed information on the Vicarious Surgical System, the company’s operating expenses, capital structure, governance and listing status.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Vicarious Surgical presents audited and interim financial statements, segment information for research and development, sales and marketing, and general and administrative activities, along with risk factors and management’s discussion of its development-stage business. Current reports on Form 8-K disclose material events such as registered direct offerings and private placements of common stock and warrants, at-the-market offering agreements, cash burn guidance, board and committee changes, and special meetings of stockholders to approve warrant exercises under New York Stock Exchange rules.
Filings also document listing and registration matters. For example, a Form 25 filed by the New York Stock Exchange relates to the removal from listing and registration of Vicarious Surgical’s publicly traded warrants, while separate 8-K items describe the NYSE’s notice to commence delisting proceedings for those warrants and the continued listing of the company’s Class A common stock under the symbol RBOT, subject to compliance with NYSE standards.
On Stock Titan, these documents are supplemented by AI-powered summaries that explain the key points of lengthy filings, such as complex financing terms, warrant structures, or at-the-market programs. Users can quickly see highlights from 10-K and 10-Q reports, understand the implications of Form 8-K events, and review proxy materials like definitive proxy statements (DEF 14A) that cover special meetings and stockholder proposals. The page also links to information about warrants, capital raises and other securities-related disclosures, helping investors and researchers analyze how Vicarious Surgical funds and governs the development of its single-port robotic surgery platform.
Adam David Sachs, a director, 10% owner and President of Vicarious Surgical Inc. (RBOT), reported a non-discretionary sale on 09/03/2025 of 463 shares of Class A common stock to satisfy tax-withholding obligations from restricted stock units granted on June 2, 2023. The transactions were executed as a "sell-to-cover" under the companys equity plan at a weighted average price of $5.7564 per share (trades ranged from $5.64 to $5.87). After the sale, the reporting person beneficially owned 49,164 shares directly. The Form 4 was submitted by an attorney-in-fact on 09/04/2025.
Vicarious Surgical Inc. (RBOT) Form 4: insider sale to cover taxes
Khalifa Sammy, listed as Chief Technology Officer, Director and a 10% owner, reported a sale of 239 shares of Class A common stock on 09/03/2025 at a weighted average price of $5.7195 per share. The filing states the sale was a mandatory "sell to cover" to satisfy tax withholding on restricted stock units granted June 2, 2023, and therefore was not a discretionary trade. After the transaction, the reporting person beneficially owned 34,515 shares. The filer signed via attorney-in-fact on 09/04/2025.
Form 144 filed for Vicarious Surgical Inc. (RBOT) discloses a proposed sale of 463 shares of Class A common stock through UBS Financial Services on 09/03/2025 with an aggregate market value of $2,685. The filing states the shares were acquired by restricted stock lapse on 09/02/2025 and lists total shares outstanding as 5,298,253. The notice also reports three prior sales by the same person during the past three months totaling 1,559 shares with aggregate gross proceeds of $10,040. The filer affirms no undisclosed material adverse information and includes standard signature and legal attestations.
Vicarious Surgical Inc. (RBOT) Form 144 shows a proposed sale of 239 shares of Class A common stock through UBS Financial Services with an aggregate market value of $1,386 and an approximate sale date of 09/03/2025 on the NYSE. The filing reports the securities were acquired on 09/02/2025 via a restricted stock lapse from Vicarious Surgical Inc. and indicates 696 shares were acquired in that transaction.
The filing also discloses three prior sales by the listed seller, Sammy Khalifa, during the past three months: 239 shares on 06/03/2025 for $1,641, 223 shares on 06/23/2025 for $1,650, and 653 shares on 08/20/2025 for $3,801. The notice includes the standard signature representation that the seller is not aware of undisclosed material adverse information about the issuer.
Donald F. Tang, a director of Vicarious Surgical Inc. (RBOT), reported an open-market sale of 2,753 shares of Class A common stock on 08/26/2025 at a weighted average price of $6.6965 per share. Following the sale, the filing shows Mr. Tang beneficially owned 40,425 shares. The Form 4 was executed by an attorney-in-fact on 08/27/2025. The filing discloses the weighted average price represents multiple trades that ranged from $6.64 to $7.15 per share, and the reporting person offers to provide trade-specific quantities and prices to SEC staff or the company on request.
Khalifa Sammy, listed as Chief Technology Officer, director and a 10% owner of Vicarious Surgical Inc. (RBOT), reported a non-discretionary sale on 08/20/2025 of 653 shares of Class A common stock to satisfy tax withholding obligations arising from restricted stock units granted on May 19, 2022. The weighted average sale price was $6.0422, with individual trades ranging from $5.90 to $6.32. After the transaction, the reporting person beneficially owned 34,754 shares directly. The Form 4 was filed by one reporting person and signed on 08/21/2025 by an attorney-in-fact.
Adam David Sachs, President and Director of Vicarious Surgical Inc. (RBOT), sold 817 shares of Class A common stock on 08/20/2025 to satisfy tax withholding on vested restricted stock units. The sales were executed as a mandatory "sell to cover" under the company's equity plan and are not discretionary trades. The weighted average sale price was $6.0312 per share, with individual trade prices ranging from $5.90 to $6.32. After the transaction Sachs beneficially owned 49,627 shares. The Form 4 was signed by an attorney-in-fact on 08/21/2025.
Director Donald F. Tang reported open-market dispositions of Vicarious Surgical Inc. (RBOT) common stock. He sold 100 shares on 08/19/2025 at $6.68 and 2,059 shares on 08/20/2025 at $6.04, reducing his direct holdings from 45,237 shares to 43,178 shares. The form is signed by an attorney-in-fact and does not disclose any derivative transactions or additional context.
Form 144 notice for Vicarious Surgical Inc. (RBOT) reports a proposed sale of Class A common stock through UBS Financial Services. The filing shows 817 shares proposed for sale with an aggregate market value of $5,212.46 and lists the approximate sale date as 08/20/2025 on the NYSE. The securities were acquired by the reporting person on 08/19/2025 as a restricted stock lapse, with 2,378 shares noted as acquired on that date. The filing also discloses three sales by the same seller in the past three months: 817 shares on 05/20/2025 for $5,961, 463 shares on 06/03/2025 for $3,210, and 279 shares on 06/23/2025 for $2,067. The notice includes the seller’s signed representation that they are not aware of any undisclosed material adverse information about the issuer.
Vicarious Surgical Inc. (RBOT) filing is a Form 144 notice reporting proposed sales of Class A common stock by an insider. The filing lists a planned sale of 653 shares through UBS Financial Services with an aggregate market value of $4,166.14 and an approximate sale date of 08/20/2025 on the NYSE. The securities were acquired on 08/19/2025 by restricted stock lapse, showing 1,902 shares acquired in that transaction. The filer also disclosed three prior sales in the past three months totaling 1,115 shares with gross proceeds of $8,039 on 05/20/2025, 06/03/2025, and 06/23/2025. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
